Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG): Evidence for Hypoglycosylation-Driven Channelopathy.

磷酸甘露糖变位酶缺乏症 (PMM2-CDG) 中的中风样发作和小脑综合征:低糖基化驱动的通道病的证据

阅读:5
作者:Izquierdo-Serra Mercè, Martínez-Monseny Antonio F, López Laura, Carrillo-García Julia, Edo Albert, Ortigoza-Escobar Juan Darío, García Óscar, Cancho-Candela Ramón, Carrasco-Marina M Llanos, Gutiérrez-Solana Luis G, Cuadras Daniel, Muchart Jordi, Montero Raquel, Artuch Rafael, Pérez-Cerdá Celia, Pérez Belén, Pérez-Dueñas Belén, Macaya Alfons, Fernández-Fernández José M, Serrano Mercedes
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG), and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM) caused by mutations in CACNA1A (encoding Ca(V)2.1 channel). The underlying pathomechanisms are unknown. We analyze clinical variables to detect risk factors for SLE in a series of 43 PMM2-CDG patients. We explore the hypothesis of abnormal Ca(V)2.1 function due to aberrant N-glycosylation as a potential novel pathomechanism of SLE and ataxia in PMM2-CDG by using whole-cell patch-clamp, N-glycosylation blockade and mutagenesis. Nine SLE were identified. Neuroimages showed no signs of stroke. Comparison of characteristics between SLE positive versus negative patients' group showed no differences. Acute and chronic phenotypes of patients with PMM2-CDG or CACNA1A channelopathies show similarities. Hypoglycosylation of both Ca(V)2.1 subunits (α(1A) and α(2α)) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic CACNA1A mutations linked to FHM and ataxia. Unoccupied N-glycosylation site N283 at α(1A) contributes to a gain-of-function by lessening Ca(V)2.1 inactivation. Hypoglycosylation of the α₂δ subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the Ca(V)2.1 channel. Ca(V)2.1 hypoglycosylation may cause ataxia and SLEs in PMM2-CDG patients. Aberrant Ca(V)2.1 N-glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。